1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Pneumococcal vaccination relatively cost efficient in Dutch elderly? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Vanadyl sulfate: hypoglycaemic and insulin sensitising effects |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Omalizumab - asthma and rhinitis therapy in the new millennium |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 7-8
Deborah Cochrane,
Carmen Innes,
Preview
|
|
摘要:
The development of omalizumab [anti-IgE monoclonal antibody E25; 'Xolair'] holds great promise as a novel treatment for asthma and allergic rhinitis. The agent is creeping closer to the market, with European and US launches expected in the fourth quarter of 2001, according to Genentech, Novartis and Tanox, the companies developing omalizumab. A number of studies demonstrating the value of this unique treatment modality were presented at the 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology [New Orleans, US; March 2001].
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Role of DSE in major vascular surgery |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Raloxifene: MORE data on cardiovascular events revealed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1284,
2001,
Page 11-12
Charles Bankhead,
Preview
|
|
摘要:
Raloxifene ['Evista'] does not increase the risk of cardiovascular events in postmenopausal women with osteoporosis, according to 3-year data from the MORE*trial which were presented recently at the 50th Scientific Session of the American College of Cardiology [Orlando, US; March 2001]. In fact, if anything, the drug showed a positive, but nonsignificant, trend towards a reduction in cardiovascular events. The data are in contrast to HERS*, which showed no overall benefit and some evidence of an early risk of thrombotic events in high-risk women who received estrogen or combined hormone replacement therapy (HRT).**Furthermore, preliminary data from the WHI*have indicated that HRT is associated with a possible increase in the risk of cardiovascular events.†
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|